Kazia Therapeutics Share Price and Company Fundamentals



Price
$1.58
Change
0.000 (0.000%)
52 week
0.77 - 1.88

Last traded: Last Friday at 6:10 AM

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key Metrics

PE ratio

-

PB ratio

5.51

Dividend yield

Beta

2.77

Market cap

$208.58M

Enterprise value

$180.99M

Company profile

Primary activitiesKazia Therapeutics partners with the world¿¿¿s leading researchers and drug developers to bring forward a diversified portfolio of new cancer therapies.
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.kaziatherapeutics.com
Mailing addressThree International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 Australia
Phone / Fax /
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Kazia Therapeutics does not pay dividends.

Company Executives

As of Sep 2021, following are the company executives and directors listed on Kazia Therapeutics.

NameTitleAgeTotal Pay
Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (CEO, MD & Exec. Director47738.46k
Ms. Gabrielle HeatonDirector of Fin. & Admin.239.96k
Ms. Catherine Jane Hill B.Sc., C.A., ACA, GAICD, BSc (Hons)Company Sec.60142.88k
Kym RobinsDirector of Marketing & Communications

Profitability and management effectiveness

Profit margin

-55.47%

Operating margin

-42.01%

Return on assets

-9.83%

Return on equity

-32.41%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Kazia Therapeutics is 208.58M and its enterprise value is 180.99M. The enterprise value to revenue ratio of KZA is 11.92.

The KZA's stocks Beta value is 2.77 making it 177% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Kazia Therapeutics (KZA)

Kazia Therapeutics (ASX:KZA) Frequently Asked Questions

1. What is Kazia Therapeutics's Stock Symbol?

Kazia Therapeutics trades on ASX under the ticker symbol "KZA".

2. What is Kazia Therapeutics's stock price today?

One share of KZA stock can currently be purchased for approximately $1.58.

3. How can I contact Kazia Therapeutics?

Kazia Therapeutics's mailing address is Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 Australia. The company can be reached via phone at .

4. What is Kazia Therapeutics's official website?

The official website of Kazia Therapeutics is http://www.kaziatherapeutics.com.

5. Which share registry manages Kazia Therapeutics's stock?

Kazia Therapeutics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.